Synthetic cells are engineered particles that mimic one or many functions of biological components. The main approach to build synthetic cells is to create a protocell entirely from non-living materials, which are composed of defined components such as amino acids, inorganic salts and vitamins. Artificially synthesized cells have same properties and functions as natural biological cells. Synthetic cells allows to change the characteristic of organisms by altering its DNA. It can be used in many fields such as healthcare, biotechnology and nanotechnology to develop novel technology or to treat genetic diseases.
Advancement in synthetic biology and introduction of advanced technologies in the field of genetic, biology, engineering and computer sciences drives the growth of this market. However, stringent regulatory policies for the use of synthetic cells pose significant problems for the growth of this market. For example, synthetic cells fall under the category of somatic cell therapies like gene therapy and cloning that typically represents high risk for the transfer of genetic materials. This regulatory policy ultimately restrains the growth of this market.
In globally, Europe dominates the global synthetic cells. Consistent efforts by the European Union (EU) for the development of synthetic cells in this region will boost the market growth. While, North America is considered as the second largest market. The growth is mainly attributed to increasing scientific research and development of novel technologies in this region. In addition, increasing investment of the U.S. government and private companies in synthetic biology research accentuates the growth of this market. Asia-Pacific region is considered as emerging market for synthetic cells owing to the support of international organizations such as Biotechnology Industry Organization (BIO) and Synthetic Biology Engineering Research Center (SynBERC) for the development of this market in Asia-Pacific region.